Impact of Bicytopenia on Mortality in Hospitalised Patients With Heart Failure.

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI:10.5334/gh.1425

Toshitaka Okabe, Tadayuki Yakushiji, Daiki Kato, Hirotoshi Sato, Toshihiko Matsuda, Yui Koyanagi, Katsuya Yoshihiro, Takeshi Okura, Yuma Gibo, Yuki Ito, Tatsuki Fujioka, Shigehiro Ishigaki, Shuro Narui, Taro Kimura, Suguru Shimazu, Yuji Oyama, Naoei Isomura, Masahiko Ochiai

{"title":"Impact of Bicytopenia on Mortality in Hospitalised Patients With Heart Failure.","authors":"Toshitaka Okabe, Tadayuki Yakushiji, Daiki Kato, Hirotoshi Sato, Toshihiko Matsuda, Yui Koyanagi, Katsuya Yoshihiro, Takeshi Okura, Yuma Gibo, Yuki Ito, Tatsuki Fujioka, Shigehiro Ishigaki, Shuro Narui, Taro Kimura, Suguru Shimazu, Yuji Oyama, Naoei Isomura, Masahiko Ochiai","doi":"10.5334/gh.1425","DOIUrl":null,"url":null,"abstract":"Background: Limited data are available on bicytopenia (BC) in patients with heart failure (HF).Objectives: This study evaluated the association between BC and prognosis in patients with HF.Methods: This retrospective cohort study enrolled consecutive hospitalised patients with HF. We compared all-cause and cardiovascular mortality between those with and without BC. BC was defined as the combination of any two conditions among leukopaenia, thrombocytopaenia, and anaemia. Propensity score matching and a Cox proportional hazards model were applied.Results: Among 935 hospitalised patients, 103 patients had BC. Patients in the BC group were older (80.0 ± 12.0 vs. 73.4 ± 14.7 years; P < 0.0001), including a higher proportion of females (55.3% vs. 41.7%; P = 0.009), had a higher prevalence of atrial fibrillation (51.5% vs 41.1%; P = 0.047), had a lower baseline estimated glomerular filtration rate (50.8 ± 24.1 vs. 56.2 ± 23.9 mL/min/1.73 m2; P = 0.03), and had a higher left ventricular ejection fraction (48.1 ± 16.1 vs. 42.4 ± 15.8%; P = 0.0008). Propensity score matching with a 1:1 ratio produced 63 matched pairs. All-cause mortality was significantly higher in the BC group than in the non-BC group (log-rank P = 0.069 and Wilcoxon P = 0.048); however, cardiovascular mortality and hospitalisation for HF showed no significant differences. In the multivariate Cox proportional hazard model, BC was associated with higher all-cause mortality but not with cardiovascular mortality (hazard ratio, 1.983; 95% confidence interval, 1.008-3.898; P = 0.047).Conclusion: BC was associated with all-cause mortality but not with cardiovascular mortality in patients with HF. BC is an important risk factor for all-cause mortality in patients with HF.","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"41"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047623/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1425","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Limited data are available on bicytopenia (BC) in patients with heart failure (HF).

Objectives: This study evaluated the association between BC and prognosis in patients with HF.

Methods: This retrospective cohort study enrolled consecutive hospitalised patients with HF. We compared all-cause and cardiovascular mortality between those with and without BC. BC was defined as the combination of any two conditions among leukopaenia, thrombocytopaenia, and anaemia. Propensity score matching and a Cox proportional hazards model were applied.

Results: Among 935 hospitalised patients, 103 patients had BC. Patients in the BC group were older (80.0 ± 12.0 vs. 73.4 ± 14.7 years; P < 0.0001), including a higher proportion of females (55.3% vs. 41.7%; P = 0.009), had a higher prevalence of atrial fibrillation (51.5% vs 41.1%; P = 0.047), had a lower baseline estimated glomerular filtration rate (50.8 ± 24.1 vs. 56.2 ± 23.9 mL/min/1.73 m²; P = 0.03), and had a higher left ventricular ejection fraction (48.1 ± 16.1 vs. 42.4 ± 15.8%; P = 0.0008). Propensity score matching with a 1:1 ratio produced 63 matched pairs. All-cause mortality was significantly higher in the BC group than in the non-BC group (log-rank P = 0.069 and Wilcoxon P = 0.048); however, cardiovascular mortality and hospitalisation for HF showed no significant differences. In the multivariate Cox proportional hazard model, BC was associated with higher all-cause mortality but not with cardiovascular mortality (hazard ratio, 1.983; 95% confidence interval, 1.008-3.898; P = 0.047).

Conclusion: BC was associated with all-cause mortality but not with cardiovascular mortality in patients with HF. BC is an important risk factor for all-cause mortality in patients with HF.

查看原文本刊更多论文

双氧体减少症对心力衰竭住院患者死亡率的影响

背景：关于心力衰竭（HF）患者双氧减少症（BC）的数据有限。目的：本研究评估心衰患者BC与预后的关系。方法：本回顾性队列研究纳入了连续住院的心衰患者。我们比较了BC患者和非BC患者的全因死亡率和心血管死亡率。BC被定义为白血病、血小板减少症和贫血中任意两种情况的结合。采用倾向评分匹配和Cox比例风险模型。结果：935例住院患者中，103例有BC。BC组患者年龄较大(80.0±12.0∶73.4±14.7岁；P < 0.0001)，其中女性比例较高(55.3%比41.7%；P = 0.009)，房颤患病率较高(51.5% vs 41.1%；P = 0.047)，基线肾小球滤过率较低(50.8±24.1 vs. 56.2±23.9 mL/min/1.73 m2；P = 0.03)，且左室射血分数较高(48.1±16.1∶42.4±15.8%；P = 0.0008)。倾向分数按1:1的比例匹配，得到63对匹配。BC组的全因死亡率显著高于非BC组（log-rank P = 0.069, Wilcoxon P = 0.048）；然而，心衰的心血管死亡率和住院率没有显著差异。在多变量Cox比例风险模型中，BC与较高的全因死亡率相关，但与心血管死亡率无关(风险比1.983；95%置信区间为1.008-3.898；P = 0.047)。结论：BC与HF患者的全因死亡率相关，但与心血管死亡率无关。BC是心衰患者全因死亡率的重要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.